Cytek Biosciences Board Member Receives New 2025 Equity Awards

Rhea-AI Filing Summary

Form 4 snapshot: On 18 June 2025 Cytek Biosciences (CTKB) reported that director Michael Holder received two equity awards – 43,973 Restricted Stock Units (RSUs) and 23,809 non-qualified stock options – both coded “A” for acquisition.

Key terms:

• RSUs: One RSU converts into one common share; no cash paid.
• Options: Exercise price set at $3.07, indicating the share price on grant date.
• Vesting for both awards: 100% on the earlier of 18 June 2026 or the 2026 annual meeting (if held in June 2026).

Post-transaction ownership: Holder now directly holds 43,973 RSUs and 23,809 options, representing a potential 67,782 new shares if fully vested and exercised. No sales, dispositions or open-market purchases were disclosed.

Investor takeaway: The filing reflects routine board compensation, aligns the director’s interests with shareholders for at least the next year and introduces only minor potential dilution relative to the company’s total shares outstanding. No information affecting earnings, cash flow or strategy was provided.

Insights

Financial Analyst

TL;DR: Routine equity grant; neutral impact; minimal dilution.

The Form 4 shows a standard annual director compensation package – 43,973 RSUs plus 23,809 options at $3.07. With vesting tied to continued service through mid-2026, the grant incentivises retention without requiring immediate cash outlay. The 67.8 k potential shares are immaterial versus CTKB’s typical >100 m share base, so dilution risk is negligible. Because no open-market sales occurred, the filing carries no bearish signalling. Overall, the transaction neither alters the firm’s capital structure in a material way nor changes its investment thesis.

Corporate Governance Expert

TL;DR: Standard board compensation; aligns incentives; governance-neutral.

The one-year cliff vesting schedule satisfies common best-practice guidelines for director equity, fostering long-term alignment without accelerating payouts. Granting options at fair-market value avoids discounted pricing concerns. No related-party issues, Rule 10b5-1 plans or group filings are indicated. Governance impact therefore remains neutral, and shareholders gain modest comfort from the director’s increased economic exposure to share performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holder Michael

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BLVD.

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2025		A		43,973		(2)	(2)	Common Stock	43,973	$0	43,973	D
Director Stock Option (right to buy)	$3.07	06/18/2025		A		23,809		(3)	06/18/2035	Common Stock	23,809	$0	23,809	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

3. 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

	/s/ Valerie Barnett, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did CTKB director Michael Holder receive on 18 June 2025?

He received 43,973 RSUs and 23,809 stock options.

What is the exercise price of the options granted to Michael Holder by Cytek Biosciences?

The options carry an exercise price of $3.07 per share.

When will the RSUs and options granted to CTKB’s director vest?

Both awards vest 100% on the earlier of 18 June 2026 or the company’s 2026 annual meeting (if held in June 2026).

Did the Form 4 filing report any insider sales of CTKB stock?

No. The filing only disclosed equity grants; no shares were sold or disposed of.

How many CTKB shares could be issued if Michael Holder’s new awards fully vest and are exercised?

Up to 67,782 shares (43,973 RSUs + 23,809 option shares).